ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS)
| CAPS Rating |
|
|---|
BIS
VS S&P 500 (SPY)
BIS News and Commentary
- Itau Unibanco Profit Falls in Q4 - Analyst Blog – NASDAQ
- The Zacks Analyst Blog Highlights: Oracle, International Business Machines, Moody's, Infosys and Zum – NASDAQ
- Oracle's New Software in Market - Analyst Blog – NASDAQ
- Gold Remains on Trajectory to Significantly Higher Prices – Minyanville
- Greco-Roman Economics - Analyst Blog – NASDAQ
- Institutional Forex: A Primer in High Frequency Trading – NASDAQ
- Growth in U.S. Drug Sales Slows – SeekingAlpha
- Why Phase II Trials Are the Best Time for Biotech Investing – SeekingAlpha
- How to Maneuver the Biotech Sector – SeekingAlpha
How do you think BIS will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
17
Outperform
47
Underperform
All-Star Players
4
Outperform
33
Underperform
Wall Street
0
Outperform
0
Underperform
RSS Headlines
Fool UK
